Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Summary

This randomized, double-blind, placebo-controlled, multi-center study will evaluate the efficacy and safety of RO6807952 in patients with diabetes mellitus type 2 inadequately controlled with metformin alone. Patients will be randomized to receive doses of RO6807952, placebo, or liraglutide. The anticipated time on study treatment is 12 weeks.

Timeline

Start

2011-11

Primary completion

2012-01

Completion

2012-01

Drugs

Indications